Tarrytown, N.Y.-based Regeneron Pharmaceuticals is teaming up with the Biomedical Advanced Research and Development Authority and HHS to create a Middle East Respiratory Syndrome treatment, according to FierceBiotech.
Here are three points:
1. The groups will develop a pair of antibodies to prevent and treat MERS.
2. HHS will allot $8.9 million to Regeneron for manufacturing, the investigational new drug application and an National Institutes of Health clinical trial.
3. Currently, no drugs exist to treat or prevent MERS.
